Case of respiratory discomfort due to myositis after administration of nivolumab

Journal of Dermatology

Volumn 42, Issue 10, 2015, Pages 1008-1009

  Yoshioka, Miri ^a   Kambe, Naotomo ^a   Yamamoto, Yosuke ^a   Suehiro, Keisuke ^a   Matsue, Hiroyuki ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETA INTERFERON; CREATINE KINASE; DACARBAZINE; DILTIAZEM; LACTATE DEHYDROGENASE; NIMUSTINE; NIVOLUMAB; TELMISARTAN; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CEREBROVASCULAR ACCIDENT; CREATINE KINASE BLOOD LEVEL; DIAPHRAGM DISEASE; DIAPHRAGMATIC ELEVATION; DYSPNEA; FATIGUE; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; INTERSTITIAL PNEUMONIA; KIDNEY INJURY; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; MALE; MELANOMA; METASTASIS; MUSCLE WEAKNESS; MYALGIA; MYOSITIS; PREOPERATIVE PERIOD; RESPIRATORY DISCOMFORT; RESPIRATORY TRACT DISEASE; RHABDOMYOLYSIS; SMOKING; THORAX RADIOGRAPHY; VERY ELDERLY; VITAL CAPACITY; CHEMICALLY INDUCED;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DYSPNEA; HUMANS; MALE; MYOSITIS;

EID: 84943372213     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12991     Document Type: Letter

References (5)

1. McDermott DF, Atkins MB,. PD-1 as a potential target in cancer therapy. Cancer Med 2013; 2: 662-673.
2. Topalian SL, Hodi FS, Brahmer JR, et al,. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
3. Yamazaki N, Tahara H, Uhara H, et al,. Phase 2 study of nivolumab (anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma. Eur J Cancer 2013; 48: S868.
4. Topalian SL, Sznol M, McDermott DF, et al,. Survival, durable tumor remission and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 986-988.
5. Min L, Hodi FS,. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolisis. Cancer Immunol Res 2014; 2: 15-18.